Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertensionheart failure and percutenous coronary interventions (PCI).

Videos | RSNA | December 18, 2019
DAIC Editor Dave Fornell and Imaging Technology News (ITN) Consulting Editor Greg Freiherr offer a post-game report on...
News | Cath Lab | December 18, 2019
December 18, 2019 — Cook Medical initiated a recall of its CrossCath Support Catheters in November, which the U.S. Food...
The most popular content in the month of November on DAIC was by far the data from the late-breaking trials from the American Herart Association (AHA) 2019 meeting. The second item on this month's list is an overview of key heart failure takeaways from AHA by Nasrien Ibrahim, M.D., associate director of resynchronization and advanced cardiac therapeutics at Massachusetts General Hospital.  Photo by Scott Morgan/AHA.

The most popular content in the month of November on DAIC was by far the data from the late-breaking trials from the American Herart Association (AHA) 2019 meeting. The second item on this month's list is an overview of key heart failure takeaways from AHA by Nasrien Ibrahim, M.D., associate director of resynchronization and advanced cardiac therapeutics at Massachusetts General Hospital.  Photo by Scott Morgan/AHA. 

Feature | December 17, 2019
December 16, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC...
Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.
Feature | Pharmaceuticals | December 16, 2019 | Dave Fornell, Editor
December 16, 2019 — The U.S. Food and Drug Administration (FDA), on Dec. 13, approved the use of Vascepa (icosapent...
 CAE Healthcare will showcase its mixed reality training solutions for practicing physicians and medical imaging companies for the first time at the Radiological Society of North America (RSNA) 2019 meeting. With technology platforms that integrate modeled human physiology into immersive, augmented reality environments, CAE Healthcare partners with vendors to deliver risk-free training solutions that meet the needs of physicians and equipment providers. #RSNA19 #RSNA2019
News | Virtual and Augmented Reality | November 27, 2019
November 27, 2019 — CAE Healthcare will showcase its mixed reality training solutions for practicing physicians and...
A sample of the transcatheter mitral valve replacement (TMVR) devices in development or clinical trials.

A sample of the transcatheter mitral valve replacement (TMVR) devices in development or clinical trials.

Feature | Heart Valve Technology | November 27, 2019 | Saipriya Iyer
The overwhelming success story for transcatheter aortic valve replacement (TAVR) moving from a science project to...
A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.

A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.

News | Heart Valve Technology | November 26, 2019 | Dave Fornell, Editor
November 26, 2019 — The preliminary one-year results of the TRILUMINATE Pivotal Study for Abbott's TriClip device, a...
The FDA cleared the IN.PACT AV drug-coated Balloon. Clinical data shows In.Pact AV DCB is Safe, reduces reinterventions and maintains access for end-stage renal disease patients undergoing dialysis
News | November 26, 2019
November 21, 2019 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic In.Pact AV drug-coated...
The percentage of women entering the cardiology workforce is low, despite the fact that half of all medical students are women. Despite the low numbers, many women have become luminaries in the field of cardiology, including Dee Dee Wang, M.D., director of advanced cardiovascular imaging at Henry Ford Hospital, pictured here.

The percentage of women entering the cardiology workforce is low, despite the fact that half of all medical students are women. Despite the low numbers, many women have become luminaries in the field of cardiology, including Dee Dee Wang, M.D., director of advanced cardiovascular imaging at Henry Ford Hospital, pictured here.

 

Blog | Cardiovascular Business | November 22, 2019
Now, more than ever, the field of cardiology needs women.  But as the national need for more cardiologists overall...
The three sites most often used for distal radial artery access are the (1) anatomic snuffbox above the scaphoid (left), (2) adjacent to the snuffbox at the trapezium bone (center), and (3) the first intermetacarpal space (right). The author’s preference is either of the first two options, although good outcomes have been reported with use of the intermetacarpal space.

The three sites most often used for distal radial artery access are the (1) anatomic snuffbox above the scaphoid (left), (2) adjacent to the snuffbox at the trapezium bone (center), and (3) the first intermetacarpal space (right). The author’s preference is either of the first two options, although good outcomes have been reported with use of the intermetacarpal space.

Feature | Radial Access | November 21, 2019 | Enrique Flores, M.D., RPVI
Interest in distal radial artery access (DRA) is growing rapidly. Among the benefits of DRA are the low risk of entry...
In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff

In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff 

Feature | AHA | November 19, 2019
November 19, 2019 — After 12 years of collecting data, the results of the landmark ISCHEMIA (International Study of...
Since Maquet/Datascope first recalled all of its  intra-aortic balloon pumps (IABP) due to reports of the batteries failing in November 2018, a year later the U.S. Food and Drug Administration said its has received more than 60 additional medical device reports related to this issue. These included two patient deaths and one serious patient injury.
News | November 19, 2019
November 19, 2019 — Since Maquet/Datascope first recalled all of its  intra-aortic balloon pumps (IABP) due to reports...
The American Heart Association, AHA, 2019 meeting late breaking trials and key studies on cardiovascular science.
Feature | AHA | November 19, 2019 | Dave Fornell, Editor
November 19, 2019 — Here is a list of the key late-breaking clinical study presentations and links to the results at...
The ClotTriever system (Inari Medical), a mechanical thrombectomy system FDA 510(k) cleared for the nonsurgical removal of soft thrombi and emboli from peripheral blood vessels.  #VIVA19 #VIVA2019

The ClotTriever system (Inari Medical), a mechanical thrombectomy system FDA 510(k) cleared for the nonsurgical removal of soft thrombi and emboli from peripheral blood vessels. 

 

News | Deep Vein Thrombosis (DVT) | November 14, 2019
November 7, 2019 — The ClotTriever Outcomes (CLOUT) Registry is evaluating real-world patient outcomes following...
News | Peripheral Artery Disease (PAD) | November 14, 2019
November 7, 2019 — Ultrasoundplasty before angioplasty for below-the-knee lesions (BTK) lesions may improve clinical...